Is Rothia mucilaginosa pathogenic?

Rothia mucilaginosa is a normal inhabitant of the human oral cavity and respiratory tract. It is an infrequent pathogen, mostly affecting severely immunocompromised patients.

What causes Rothia mucilaginosa?

are Gram-positive cocco-bacilli that cause a wide range of serious infections, especially in immunocompromised hosts. Risk factors for Rothia mucilaginosa (previously known as Stomatococcus mucilaginosus) bacteremia include prolonged and profound neutropenia, malignancy, and an indwelling vascular foreign body.

Where is Rothia mucilaginosa found?

Rothia mucilaginosa, previously Stomatococcus mucilaginosus, is an aerobic, gram-positive coccus belonging to the family Micrococcaceae. It is found in the oropharynx and upper respiratory tract as part of the normal flora [1] and was first isolated from an endocarditis patient in 1978 [2].

Is Rothia aerobic?

Rothia is a Gram-positive, aerobic, rod-shaped and non-motile bacterial genus from the family of Micrococcaceae. Rothia bacteria can cause disease in humans and immunosuppressed humans.

What antibiotic covers Micrococcus luteus?

In contrast to staphylococci (for which it may easily be mistaken) it is usually penicillin-sensitive. However, the most promising antibiotic regimen proposed for treatment of Micrococcus luteus seems to be a combination of vancomycin, amikacin, and rifampicin.

What kills Micrococcus luteus?

Lysozyme. Lysozyme was described by Fleming, who noted both its wide distribution and its remarkable ability to lyse certain gram-positive bacteria, such as Micrococcus lysodeikticus. Lysozyme is a very cationic protein of approximately 14.4 kDa.

What are the treatment options for Rothia mucilaginosa (Rothia infections)?

They are intrinsically resistant to vancomycin; therapy has traditionally been with β-lactams, but the successful use of daptomycin has also recently been reported. 165 Miquel B. Ekkelenkamp, Marc J.M. Bonten, in Infectious Diseases (Third Edition), 2010 Rothia mucilaginosa is a normal inhabitant of the human oral cavity and respiratory tract.

What are the treatment options for Enterobacter mucilaginosa pneumonia?

Beta-lactams or vancomycin alone or in combination with other antibiotics have been successfully used for the treatment of R. mucilaginosa pneumonia. The outcome was favourable in 18 cases. Only one fatality was attributed to the infection. Conclusion: R. mucilaginosa should be considered in the diagnosis of pneumonia in both immunocompromised

Does Rothia mucilaginosa induce COX-2?

The inhibition of COX-2 improved survival in mice, suggesting that the pathogenic effects of R. mucilaginosa are related to the induction of COX-2 It is also closely associated with Bacteremia, sepsis, and endocarditis. Rothia mucilaginosa is resistant to the quinolone class of antibiotics, with extreme resistance to fluoroquinolones.

What is the prevalence of Rothia mucilaginosa bacteremia in pediatric cancer patients?

Among a cohort of 1511 hematologic-oncologic patients at a pediatric tertiary care cancer center, we identified five cancer patients (0.35%) within a period of 10 years having a proven Rothia mucilaginosa bacteremia (1 culture positive: n = 3/5; > 1 culture positive: n = 2/5).